EA200800100A1 - Соединения азаиндазола и способы применения - Google Patents
Соединения азаиндазола и способы примененияInfo
- Publication number
- EA200800100A1 EA200800100A1 EA200800100A EA200800100A EA200800100A1 EA 200800100 A1 EA200800100 A1 EA 200800100A1 EA 200800100 A EA200800100 A EA 200800100A EA 200800100 A EA200800100 A EA 200800100A EA 200800100 A1 EA200800100 A1 EA 200800100A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- methods
- ccr1
- azaindazol
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Описываются соединения, которые действуют как потенциальные антагонисты рецептора CCR1 и имеют противовоспалительную активность in vivo. Соединения, в целом, представляют собой арилпиперазиновые производные и применимы в фармацевтических композицях, способах лечения опосредуемых CCR1 заболеваний и как контрольные соединения в анализах для идентификации конкурентных антагонистов CCR1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69352505P | 2005-06-22 | 2005-06-22 | |
PCT/US2006/024313 WO2007002293A2 (en) | 2005-06-22 | 2006-06-22 | Azaindazole compounds and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
EA200800100A1 true EA200800100A1 (ru) | 2008-06-30 |
EA017278B1 EA017278B1 (ru) | 2012-11-30 |
EA017278B9 EA017278B9 (ru) | 2013-01-30 |
Family
ID=37595833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200800100A EA017278B9 (ru) | 2005-06-22 | 2006-06-22 | Соединения азаиндазола и способы применения |
Country Status (27)
Country | Link |
---|---|
US (2) | US7524845B2 (ru) |
EP (1) | EP1906965B1 (ru) |
JP (1) | JP5275794B2 (ru) |
KR (2) | KR101418024B1 (ru) |
CN (1) | CN101242839B (ru) |
AU (1) | AU2006262122B2 (ru) |
BR (1) | BRPI0612112A8 (ru) |
CA (1) | CA2612552C (ru) |
DK (1) | DK1906965T3 (ru) |
EA (1) | EA017278B9 (ru) |
ES (1) | ES2543714T3 (ru) |
HK (1) | HK1124241A1 (ru) |
HR (1) | HRP20150832T1 (ru) |
HU (1) | HUE025476T2 (ru) |
IL (1) | IL188050A (ru) |
MA (1) | MA29568B1 (ru) |
MX (1) | MX2007015917A (ru) |
NO (1) | NO340621B1 (ru) |
NZ (1) | NZ564258A (ru) |
PL (1) | PL1906965T3 (ru) |
PT (1) | PT1906965E (ru) |
RS (1) | RS54206B1 (ru) |
SG (2) | SG10201504801VA (ru) |
SI (1) | SI1906965T1 (ru) |
UA (1) | UA95777C2 (ru) |
WO (2) | WO2007002667A2 (ru) |
ZA (2) | ZA200800309B (ru) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US7777035B2 (en) * | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
MX2007015917A (es) | 2005-06-22 | 2008-03-10 | Chemocentryx Inc | Compuestos de azaindazol y metodos de uso. |
EP2557080A1 (en) | 2006-04-04 | 2013-02-13 | The Regents of The University of California | Method for identifying pI3-kinase antagonists |
US20090252779A1 (en) * | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
PT2155712T (pt) * | 2007-05-22 | 2016-12-13 | Chemocentryx Inc | 3-(imidazolil)-pirazolo[3,4-b]piridinas |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
EP2285783B1 (en) | 2008-04-29 | 2014-05-21 | Boehringer Ingelheim International GmbH | Indazole compounds as ccr1 receptor antagonists |
JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1アンタゴニストとしてのピラゾール化合物 |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン, エルエルシー | キナーゼインヒビターおよび使用方法 |
US8343975B2 (en) | 2008-09-11 | 2013-01-01 | Penglie Zhang | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
PE20110854A1 (es) | 2008-09-26 | 2011-12-23 | Boehringer Ingelheim Int | DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 |
WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
AU2009308687A1 (en) * | 2008-11-03 | 2010-05-06 | Chemocentryx, Inc. | Compounds for the treatment of osteoporosis and cancers |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US8362249B2 (en) * | 2009-04-27 | 2013-01-29 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
JP5807971B2 (ja) * | 2009-04-27 | 2015-11-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cxcr3受容体アンタゴニスト |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
BR112012002130A2 (pt) * | 2009-08-03 | 2015-09-15 | Aziende Chimique Riunite Angelini Francesco A C R A F S P A | processo para a preparação de composto,e, composto intermediário |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
SI2491028T1 (sl) * | 2009-10-21 | 2014-03-31 | Boehringer Ingelheim International Gmbh | Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1 |
JP5542214B2 (ja) | 2009-10-27 | 2014-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1受容体アンタゴニストとしての複素環化合物 |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
PL3181133T3 (pl) | 2010-12-20 | 2019-12-31 | Pfizer Inc. | Nowe skondensowane związki pirydyny jako inhibitory kinazy kazeiny |
WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
GB2488752A (en) * | 2011-02-21 | 2012-09-12 | Sony Dadc Austria Ag | Microfluidic Device |
AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
AU2012284091B2 (en) | 2011-07-19 | 2015-11-12 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CN103998442B (zh) | 2011-08-29 | 2016-09-14 | 无限药品股份有限公司 | 杂环化合物及其用途 |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
WO2013037411A1 (en) | 2011-09-14 | 2013-03-21 | Proximagen Limited | New enzyme inhibitor compounds |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
KR102196366B1 (ko) | 2012-12-07 | 2020-12-30 | 케모센트릭스, 인크. | 디아졸 락탐 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
MX363432B (es) | 2013-07-22 | 2019-03-22 | Idorsia Pharmaceuticals Ltd | Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona. |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
CN105801574A (zh) * | 2014-12-31 | 2016-07-27 | 上海药谷药业有限公司 | 一种1H-吡唑并[3,4-b]吡啶化合物的制备方法 |
DK3245203T3 (en) | 2015-01-15 | 2019-02-18 | Idorsia Pharmaceuticals Ltd | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS |
AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
IL261998B2 (en) * | 2016-04-07 | 2023-03-01 | Chemocentryx Inc | Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP7054681B2 (ja) | 2016-06-24 | 2022-04-14 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 組合せ療法 |
CN108570049A (zh) * | 2018-07-24 | 2018-09-25 | 上海毕得医药科技有限公司 | 一种6-氯-1氢-吡唑并[3,4-b]吡啶的合成方法 |
CN108794470B (zh) * | 2018-07-25 | 2020-06-26 | 上海毕得医药科技有限公司 | 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法 |
CN110343103A (zh) * | 2019-07-04 | 2019-10-18 | 深圳市格物致欣化学技术有限公司 | 吡唑并吡啶类化合物及其制备方法 |
EP3996711A4 (en) | 2019-07-10 | 2023-08-16 | ChemoCentryx, Inc. | INDANES AS PD-L1 INHIBITORS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE47467B1 (en) * | 1977-10-26 | 1984-03-21 | Wellcome Found | Imidazoline derivatives and their salts |
AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
US4927942A (en) * | 1988-12-15 | 1990-05-22 | Texaco Chemical Co. | Method for the preparation of imidazoles |
AU8645401A (en) * | 2000-08-14 | 2002-02-25 | Ortho Mcneil Pharm Inc | Substituted pyrazoles |
RU2286343C2 (ru) * | 2001-08-10 | 2006-10-27 | Орто-Макнейл Фармасьютикал, Инк. | Замещенные пиразолы |
HUP0401735A3 (en) * | 2001-10-22 | 2005-06-28 | Pfizer Prod Inc | Piperazine derivatives with ccr1 receptor antagonist activity and pharmaceutical compositions containing them |
US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
EP1531822B1 (en) * | 2002-06-12 | 2009-08-05 | ChemoCentryx Inc | 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders |
US7842693B2 (en) * | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
US7435831B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
US7435830B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
MX2007015917A (es) * | 2005-06-22 | 2008-03-10 | Chemocentryx Inc | Compuestos de azaindazol y metodos de uso. |
-
2006
- 2006-06-22 MX MX2007015917A patent/MX2007015917A/es active IP Right Grant
- 2006-06-22 WO PCT/US2006/024969 patent/WO2007002667A2/en active Application Filing
- 2006-06-22 KR KR1020077031045A patent/KR101418024B1/ko active IP Right Grant
- 2006-06-22 WO PCT/US2006/024313 patent/WO2007002293A2/en active Application Filing
- 2006-06-22 PT PT67737734T patent/PT1906965E/pt unknown
- 2006-06-22 ES ES06773773.4T patent/ES2543714T3/es active Active
- 2006-06-22 RS RS20150517A patent/RS54206B1/en unknown
- 2006-06-22 ZA ZA200800309A patent/ZA200800309B/xx unknown
- 2006-06-22 UA UAA200800722A patent/UA95777C2/uk unknown
- 2006-06-22 JP JP2008518388A patent/JP5275794B2/ja active Active
- 2006-06-22 SG SG10201504801VA patent/SG10201504801VA/en unknown
- 2006-06-22 NZ NZ564258A patent/NZ564258A/en not_active IP Right Cessation
- 2006-06-22 BR BRPI0612112A patent/BRPI0612112A8/pt not_active Application Discontinuation
- 2006-06-22 EA EA200800100A patent/EA017278B9/ru not_active IP Right Cessation
- 2006-06-22 DK DK06773773.4T patent/DK1906965T3/en active
- 2006-06-22 US US11/474,132 patent/US7524845B2/en active Active
- 2006-06-22 SG SG201004298-4A patent/SG162807A1/en unknown
- 2006-06-22 PL PL06773773T patent/PL1906965T3/pl unknown
- 2006-06-22 AU AU2006262122A patent/AU2006262122B2/en active Active
- 2006-06-22 CA CA2612552A patent/CA2612552C/en active Active
- 2006-06-22 HU HUE06773773A patent/HUE025476T2/en unknown
- 2006-06-22 EP EP20060773773 patent/EP1906965B1/en active Active
- 2006-06-22 KR KR1020147002448A patent/KR20140026644A/ko not_active Application Discontinuation
- 2006-06-22 CN CN2006800304091A patent/CN101242839B/zh active Active
- 2006-06-22 US US11/474,130 patent/US20070010523A1/en not_active Abandoned
- 2006-06-22 SI SI200631957T patent/SI1906965T1/sl unknown
-
2007
- 2007-12-11 IL IL188050A patent/IL188050A/en active IP Right Grant
- 2007-12-26 MA MA30516A patent/MA29568B1/fr unknown
-
2008
- 2008-01-21 NO NO20080408A patent/NO340621B1/no not_active IP Right Cessation
-
2009
- 2009-02-12 HK HK09101322.8A patent/HK1124241A1/xx unknown
- 2009-03-16 ZA ZA2009/01845A patent/ZA200901845B/en unknown
-
2015
- 2015-08-04 HR HRP20150832TT patent/HRP20150832T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
EA200901583A1 (ru) | N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
DE602005027707D1 (de) | Isoindolin-verbindungen und deren verwendungen | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
EA200800564A1 (ru) | Производные ксантина как селективные агонисты нм74а | |
CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
EA200970113A1 (ru) | Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н | |
EA201001522A1 (ru) | Новые p2x7r антагонисты и их применение | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
EP2155203A4 (en) | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | |
DE602008003404D1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
PT1853232E (pt) | Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização | |
EA201190236A1 (ru) | Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью | |
BRPI0918517B8 (pt) | composto, composição farmacêutica, e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |